Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (VI) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: The present invention relates to novel compounds of formula (I) or a pharmaceutically acceptable salt or solvate thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example as modulators of the growth hormone secretagogue receptor (also referred to as the ghrelin receptor or GHSRla receptor) and/or for the treatment and/or prophylaxis of a disorder mediated by the ghrelin receptor.

Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: The purpose of this invention is to provide a compound for preventing or treating an ocular disease and a pharmaceutical composition comprising the same. This invention provides a pharmaceutical composition comprising a compound as defined by the formula (I?) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is useful for preventing or treating an ocular disease such as retinochoroidal degeneration.

Abstract: This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.

Abstract: The purpose of the present invention is to provide an adsorbent composition which can be easily formed into a film by inflation molding at relatively low temperatures even if zeolite is contained therein, and which is not susceptible to the formation of a pin hole. An adsorbent composition which is a resin composition containing a resin, zeolite and a metal soap, and wherein the metal soap contains a long-chain fatty acid calcium, which is a divalent salt of calcium and a long-chain fatty acid having 5-30 carbon atoms, and a long-chain fatty acid zinc, which is a divalent salt of zinc and a long-chain fatty acid having 5-30 carbon atoms.

Abstract: The purpose of this invention is to provide a compound for preventing or treating an ocular disease and a pharmaceutical composition comprising the same. This invention provides a pharmaceutical composition comprising a compound as defined by the formula (I?) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition is useful for preventing or treating an ocular disease such as retinochoroidal degeneration.

Abstract: A laminated sheet or a container includes: an absorbing layer absorbing at least one of liquid and gas; a reinforcing layer laminated on the absorbing layer with an adhesive layer interposed therebetween; an aluminum layer laminated on the reinforcing layer with an adhesive layer interposed therebetween; and a barrier layer laminated on the aluminum layer with an adhesive layer interposed therebetween and suppressing entry of at least one of liquid and gas.

Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.

Abstract: Provided is a package that exhibits satisfactory moldability as well as moisture adsorption and gas adsorption properties. A package P includes a container sheet 6 in which a concave receptacle unit 5 that accommodates a solid preparation 8 containing solifenacin succinate or 1-{[?-isobutanoyloxyethoxy]carbonyl}aminomethyl}-1-cyclohexaneacetic acid is formed, and an airtight cover material sheet 7 for sealing the solid preparation 8. The container sheet 6 is formed by a package film F1 in which an adsorption layer 1, at least one or more substrate layers 2 formed by resins, an aluminum foil 3, and a barrier layer 4. The adsorption layer 1 is laminated with the substrate layer 2 while also being disposed on the side where the solid preparation 8 is accommodated, and contains at least zeolite.

Abstract: This invention relates to a compound with EP4 antagonistic activity, or a pharmaceutically acceptable salt with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof with EP4 receptor antagonistic activities, which is useful in the treatment of immune disease or allergy. This invention also relates to a pharmaceutical composition for the treatment of immune disease or allergy which comprises a therapeutically effective amount of a compound of formula (I), (II), (III), (IV), (Va) or (Vb), or a pharmaceutically acceptable salt thereof.

Abstract: A packaging bag and a drying agent with a moisture absorption indicator function are provided without using a heavy metal harmful to the human body. The packaging bag includes a first packaging material (10) and a second packaging material (20). The first packaging material (10) is provided on an outermost side thereof with a transparent barrier film (12) having a barrier property against water vapor. The second packaging material (20) has a light-reflective or light-absorbing film (24) and a pattern printed layer (23) overlaid on a bag interior side thereof, the pattern printed layer (23) having a printed moisture-absorbing indicator pattern (30). A desiccant-containing resin film (11, 21) which becomes transparent due to moisture absorption is overlaid on a bag interior side of at least one of the first packaging material (10) and the second packaging material (20).

Abstract: The present invention relates to a use of a compound having an acid pump antagonistic activity, a pharmaceutically acceptable salt thereof or a pharmaceutical composition thereof for the manufacture of a medicament for prevention or treatment of diseases in which abnormal gastrointestinal motility is involved. In addition, the present invention relates to the method of prevention or treatment including administering to a human or animal. The compound, the pharmaceutically acceptable salt thereof, or pharmaceutical compositions containing them, may be used in combination with one or more second active agent. Further, the present invention relates to pharmaceutical compositions and kits comprising a compound having an acid pump antagonistic activity or a pharmaceutically acceptable salt thereof for the prevention or treatment of said diseases.

Abstract: This invention provides a medicament for the treatment of cancer, which cause a reduction of cancer. This invention relates to use of a compound which has inhibitory activities against prostaglandin E2 receptor (EP4 receptor) and is represented by the following general formula (I), (II), (III), or (IV), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt for the manufacture of a medicament for the treatment of cancer. The invention relates to a method for treatment of cancer comprising administering the compound or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the compound or the salt to humans or animals. The compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition may be used in combination with one or more second active agents.

Abstract: ?-Amino hydroxamic acid derivative of the formula I, in which R is C2-C7-alkyl, which is mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3-C5-cycloalkyl or unsubstituted or substituted C3-C6-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; or C3-C7-alkenyl or C3-C7-alkynyl, which in each case is unsubstituted or mono-, di- or trisubstituted by halogen, nitro, lower acyloxy, trifluoromethoxy, cyano, C3-C5-cycloalkyl or unsubstituted or substituted C3-C6-heteroaryl comprising one or two heteroatoms selected from the group consisting of O, S and N; and the other symbols are as defined in claim 1, are described. These compounds are MMP and in particular MMP2 inhibitors and can be used for treatment of MMP dependent diseases, in particular inflammation conditions, rheumatoid arthritis, osteoarthritis, tumors (tumor growth, metastasis, progression or invasion) and pulmonary disorders (e.g. emphysema, COPD).

Abstract: A packaging bag and a drying agent with a moisture absorption indicator function are provided without using a heavy metal harmful to the human body. The packaging bag includes a first packaging material (10) and a second packaging material (20). The first packaging material (10) is provided on an outermost side thereof with a transparent barrier film (12) having a barrier property against water vapor. The second packaging material (20) has a light-reflective or light-absorbing film (24) and a pattern printed layer (23) overlaid on a bag interior side thereof, the pattern printed layer (23) having a printed moisture-absorbing indicator pattern (30). A desiccant-containing resin film (11, 21) which becomes transparent due to moisture absorption is overlaid on a bag interior side of at least one of the first packaging material (10) and the second packaging material (20).

Abstract: A packaging bag and a drying agent with a moisture absorption indicator function are provided without using a heavy metal harmful to the human body. The packaging bag includes a first packaging material (10) and a second packaging material (20). The first packaging material (10) is provided on an outermost side thereof with a transparent barrier film (12) having a barrier property against water vapor. The second packaging material (20) has a light-reflective or light-absorbing film (24) and a pattern printed layer (23) overlaid on a bag interior side thereof, the pattern printed layer (23) having a printed moisture-absorbing indicator pattern (30). A desiccant-containing resin film (11, 21) which becomes transparent due to moisture absorption is overlaid on a bag interior side of at least one of the first packaging material (10) and the second packaging material (20).

Abstract: A moisture absorbent material (drying material) with an indicator function is provided without the use of cobalt chloride containing a heavy metal, low molecular organic substance and the like; and a humidity indicator permitting a state of humidity to be found in a simple manner is also provided. The moisture absorbent material with an indicator function (10) includes a resin layer (11) containing 5 to 80 wt % zeolite which is provided on at least one surface thereof with a printed layer including a character, shape, picture or the like, so that the printed layer may visibly appear due to the resin layer becoming transparent by moisture absorption.